Monopar Therapeutics (MNPR) Net Income towards Common Stockholders (2017 - 2025)

Monopar Therapeutics has disclosed Net Income towards Common Stockholders across 9 years of filings, most recently posting -$3.4 million for Q3 2025.

• Net Income towards Common Stockholders for Q3 2025 came in at -$3.4 million, down 132.97% year-over-year; the trailing twelve-month figure through Dec 2025 was -$8.5 million (down 76.24% YoY), and the FY2024 annual result was -$15.6 million, down 85.94% from the prior year.
• Net Income towards Common Stockholders came in at -$3.4 million for Q3 2025 at Monopar Therapeutics, down from -$2.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.5 million in Q3 2024 to a low of -$14.1 million in Q4 2022.
• The 5-year median for Net Income towards Common Stockholders is -$2.4 million (2023), against an average of -$3.0 million.
• Across the five-year window, Net Income towards Common Stockholders plunged 424.06% in 2022 and surged 32.59% in 2024, its largest moves.
• Monopar Therapeutics' Net Income towards Common Stockholders stood at -$2.7 million in 2021, then slumped by 424.06% to -$14.1 million in 2022, then surged by 86.1% to -$2.0 million in 2023, then advanced by 24.47% to -$1.5 million in 2024, then slumped by 132.97% to -$3.4 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$3.4 million (Q3 2025), -$2.5 million (Q2 2025), and -$2.6 million (Q1 2025), per Business Quant data.